Anula Jayasuriya - 01 Jul 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Director
Signature
/s/ Grant Harbert, as Attorney-in-Fact
Issuer symbol
LCTX
Transactions as of
01 Jul 2022
Transactions value $
$0
Form type
4
Filing time
06 Jul 2022, 16:15:54 UTC
Previous filing
01 Jul 2021
Next filing
06 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Stock Option (right to buy) Award $0 +50,000 $0 50,000 01 Jul 2022 Common Shares 50,000 $1.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Will vest and become exercisable on July 1, 2023, subject to the reporting person's continuous service with the issuer.